Maybe investors are starting to understand that this is serious business in clinical research & treatment globally, and not some kind of whacko anti-aging thing.
You can understand, because this bio-technology is relatively new, and now moving forward in clinical research for diagnostics & treatment. Looking at what EX1 have in the pipeline for the near future, these age related diseases are common & even affect younger to middle aged people.
Wounds: well any age, but much harder to heal in the elderly & those with chronic disease (ie diabetes, PVD, infected surgical wounds, God forbid, but it happens). That one will be phenomenal if Plexaris does well in clinical trials. DYOR (please share & grateful to those that do). IMO. GLTAH
